公开(公告)号：WO2021130701A1

公开(公告)日：2021-07-01

申请号：PCT/IB2020/062407

申请日：2020-12-23

Applicant: GAMBRO LUNDIA AB

Inventor： POUCHOULIN, Dominique

IPC: A61M1/36 ,  A61M1/16 ,  A61M1/34 ,  A61M1/1611 ,  A61M1/341 ,  A61M1/3431 ,  A61M1/3437 ,  A61M1/3441 ,  A61M1/3458 ,  A61M1/3609 ,  A61M1/3672 ,  A61M1/3675 ,  A61M2205/3331 ,  A61M2205/3334 ,  A61M2205/3393

Abstract: A CRRT apparatus comprising a filtration unit (2), a blood circuit (17), a blood pump (21), a dialysate line (13) and one or more lines (8; 51; 57; 58; 63; 69; 67; 74) to transfer a respective solution into blood; a fluid source for each of said one or more lines, wherein said solution comprises at least one buffer agent in the form of bicarbonate or bicarbonate precursor. A control unit (12) is configured to receive a patient prescription and to determine a parameter (Jbuffer_load/BW) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment, wherein said parameter is determined as a function of the concentration of said buffer agent in said fluid source and as a function of the estimated or calculated patient systemic steady state concentration of bicarbonate and/or bicarbonate precursors.

公开(公告)号：WO2021216730A2

公开(公告)日：2021-10-28

申请号：PCT/US2021/028428

申请日：2021-04-21

Applicant: NXSTAGE MEDICAL, INC.

Inventor： TREU, Dennis M. ,  JAMES, Jerome ,  BURBANK, Jeffrey H. ,  RUBERY, JR., Daniel Joseph

IPC: A61M1/14 ,  A61M1/16 ,  A61M1/36 ,  A61M1/00 ,  B01D61/28 ,  B01D61/32 ,  A61M1/1647 ,  A61M1/1692 ,  A61M1/341 ,  A61M1/342 ,  A61M1/3441 ,  A61M1/3626 ,  A61M1/3643 ,  A61M1/3646 ,  A61M1/3656 ,  A61M1/367 ,  A61M2205/12 ,  A61M2205/14 ,  A61M2205/15 ,  A61M2205/18 ,  A61M2205/331 ,  A61M2205/3331 ,  A61M2205/502 ,  A61M2205/7554 ,  A61M60/104

Abstract: The disclosed subject matter relates to extracorporeal blood processing or other processing of fluids. Volumetric fluid balance, a required element of many such processes, may be achieved with multiple pumps or other proportioning or balancing devices which are to some extent independent of each other. This need may arise in treatments that involve multiple fluids. Safe and secure mechanisms to ensure fluid balance in such systems are described.

公开(公告)号：WO2022240488A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/022141

申请日：2022-03-28

Applicant: FRESENIUS MEDICAL CARE HOLDINGS, INC.

Inventor： DOYLE, Matthew ,  ZIMMERMAN, Robert, Anthony

IPC: A61M1/36 ,  A61M1/16 ,  A61M1/1635 ,  A61M1/3403 ,  A61M1/3441 ,  A61M1/3479 ,  A61M1/365 ,  A61M2205/7554

Abstract: An extracorporeal blood treatment device and a method are provided for removing a secondary membrane formed on a semipermeable membrane of a dialyzer during an extracorporeal blood treatment. The extracorporeal blood treatment device operates in a first operating mode in which a dialysate outlet valve is open such that dialysate flows through a dialyzer feed line, through a dialysate chamber, and into and through a dialyzer discharge line. The extracorporeal blood treatment device operates in a second operating mode to remove the secondary membrane from the semipermeable membrane. During the second operating mode, the dialysate outlet valve is closed for a duration of time such that dialysate is prevented from flowing through the dialyzer discharge line. A backflush procedure results wherein a volume of dialysate passes from the dialysate chamber through the semipermeable membrane and into the blood chamber.